TANG Kai 1 , LUO Mingyao 1,2,3 , SHU Chang 1,2
  • 1. State Key Laboratory of Cardiovascular Disease, Center of Vascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, P. R. China;
  • 2. Department of Vascular Surgery, Fuwai Central China Cardiovascular Hospital, Zhengzhou University Central China Fuwai Hospital, Zhengzhou, 450046, P. R. China;
  • 3. Department of Vascular Surgery, Fuwai Yunnan Cardiovascular Hospital, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming, 6501032, P. R. China;
LUO Mingyao, Email: luomingyao@fuwai.com
Export PDF Favorites Scan Get Citation

In recent years, the worldwide incidence rate of peripheral artery and aortic diseases has increased year by year, significantly increasing the cardiovascular mortality and incidence rate of the whole population. In the past, peripheral artery and aortic diseases were often more prone to missed diagnosis and delayed treatment compared to coronary artery disease. The 2024 ESC guidelines for the management of peripheral arterial and aortic diseases for the first time combines peripheral arterial and aortic diseases, integrating and updating the 2017 guidelines for peripheral arterial disease and the 2014 guidelines for aortic disease. The aim is to provide standardized recommendations for the management of systemic arterial diseases, ensuring that patients can receive coherent and comprehensive diagnosis and treatment, thereby improving prognosis. This article interprets the main content of the guideline in order to provide reference and assistance for the clinical diagnosis and treatment of peripheral artery and aortic diseases in China at the current stage.